Septerna Submits Filing for Proposed IPO

Septerna (SEPN) has submitted a proposal for an initial public offering (IPO).

The company positions itself as a clinical-stage biotechnology firm that is at the forefront of G protein-coupled receptor (GPCR) oral small molecule drug discovery, utilizing its proprietary Native Complex Platform. This large-scale platform is designed to harness the full capabilities of GPCR therapies, resulting in a robust pipeline of product candidates targeting three main therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities will act as underwriters for the offering.